Literature DB >> 21748340

A novel transcript of cyclin-dependent kinase-like 5 (CDKL5) has an alternative C-terminus and is the predominant transcript in brain.

Sarah L Williamson1, Laura Giudici, Charlotte Kilstrup-Nielsen, Wendy Gold, Gregory J Pelka, Patrick P L Tam, Andrew Grimm, Dionigio Prodi, Nicoletta Landsberger, John Christodoulou.   

Abstract

The X-linked cyclin-dependent kinase-like 5 (CDKL5) gene is an important molecular determinant of early-onset intractable seizures with infantile spasms and Rett syndrome-like phenotype. The gene encodes a kinase that may influence components of molecular pathways associated with MeCP2. In humans there are two previously reported splice variants that differ in the 5' untranslated exons and produce the same 115 kDa protein. Furthermore, very recently, a novel transcript including a novel exon (16b) has been described. By aligning both the human and mouse CDKL5 proteins to the orthologs of other species, we identified a theoretical 107 kDa isoform with an alternative C-terminus that terminates in intron 18. In human brain and all other tissues investigated except the testis, this novel isoform is the major CDKL5 transcript. The detailed characterisation of this novel isoform of CDKL5 reveals functional and subcellular localisation attributes that overlap greatly, but not completely, with that of the previously studied human CDKL5 protein. Considering its predominant expression in the human and mouse brain, we believe that this novel isoform is likely to be of primary pathogenic importance in human diseases associated with CDKL5 deficiency, and suggest that screening of the related intronic sequence should be included in the molecular genetic analyses of patients with a suggestive clinical phenotype.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21748340     DOI: 10.1007/s00439-011-1058-x

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  43 in total

1.  CDKL5 is a brain MeCP2 target gene regulated by DNA methylation.

Authors:  Delphine Carouge; Lionel Host; Dominique Aunis; Jean Zwiller; Patrick Anglard
Journal:  Neurobiol Dis       Date:  2010-03-06       Impact factor: 5.996

2.  An isoform of the severe encephalopathy-related CDKL5 gene, including a novel exon with extremely high sequence conservation, is specifically expressed in brain.

Authors:  Yann Fichou; Juliette Nectoux; Nadia Bahi-Buisson; Jamel Chelly; Thierry Bienvenu
Journal:  J Hum Genet       Date:  2010-12-02       Impact factor: 3.172

3.  Selective dendritic alterations in the cortex of Rett syndrome.

Authors:  D Armstrong; J K Dunn; B Antalffy; R Trivedi
Journal:  J Neuropathol Exp Neurol       Date:  1995-03       Impact factor: 3.685

4.  CDKL5 expression is modulated during neuronal development and its subcellular distribution is tightly regulated by the C-terminal tail.

Authors:  Laura Rusconi; Lisa Salvatoni; Laura Giudici; Ilaria Bertani; Charlotte Kilstrup-Nielsen; Vania Broccoli; Nicoletta Landsberger
Journal:  J Biol Chem       Date:  2008-08-13       Impact factor: 5.157

5.  A CDKL5 mutated child with precocious puberty.

Authors:  Veronica Saletti; Laura Canafoglia; Paola Cambiaso; Silvia Russo; Margherita Marchi; Daria Riva
Journal:  Am J Med Genet A       Date:  2009-05       Impact factor: 2.802

6.  A novel p.Arg970X mutation in the last exon of the CDKL5 gene resulting in late-onset seizure disorder.

Authors:  Stavroula Psoni; Patrick J Willems; Emmanuel Kanavakis; Ariadne Mavrou; Helen Frissyra; Joanne Traeger-Synodinos; Christalena Sofokleous; Periklis Makrythanassis; Sophia Kitsiou-Tzeli
Journal:  Eur J Paediatr Neurol       Date:  2009-05-09       Impact factor: 3.140

Review 7.  Mutational spectrum of CDKL5 in early-onset encephalopathies: a study of a large collection of French patients and review of the literature.

Authors:  C Nemos; L Lambert; F Giuliano; B Doray; A Roubertie; A Goldenberg; B Delobel; V Layet; M A N'guyen; A Saunier; F Verneau; P Jonveaux; C Philippe
Journal:  Clin Genet       Date:  2009-10       Impact factor: 4.438

8.  Novel mutations in the CDKL5 gene, predicted effects and associated phenotypes.

Authors:  S Russo; M Marchi; F Cogliati; M T Bonati; M Pintaudi; E Veneselli; V Saletti; M Balestrini; B Ben-Zeev; L Larizza
Journal:  Neurogenetics       Date:  2009-02-25       Impact factor: 2.660

9.  CDKL5/STK9 is mutated in Rett syndrome variant with infantile spasms.

Authors:  E Scala; F Ariani; F Mari; R Caselli; C Pescucci; I Longo; I Meloni; D Giachino; M Bruttini; G Hayek; M Zappella; A Renieri
Journal:  J Med Genet       Date:  2005-02       Impact factor: 6.318

10.  CDKL5/Stk9 kinase inactivation is associated with neuronal developmental disorders.

Authors:  Clark Lin; Brunella Franco; Marsha Rich Rosner
Journal:  Hum Mol Genet       Date:  2005-12-05       Impact factor: 6.150

View more
  23 in total

1.  Aminoglycoside drugs induce efficient read-through of CDKL5 nonsense mutations, slightly restoring its kinase activity.

Authors:  Maria Fazzari; Angelisa Frasca; Francesco Bifari; Nicoletta Landsberger
Journal:  RNA Biol       Date:  2019-06-23       Impact factor: 4.652

2.  Neurodevelopmental and neurobehavioral characteristics in males and females with CDKL5 duplications.

Authors:  Przemyslaw Szafranski; Sailaja Golla; Weihong Jin; Ping Fang; Patricia Hixson; Reuben Matalon; Daniel Kinney; Hans-Georg Bock; William Craigen; Janice L Smith; Weimin Bi; Ankita Patel; Sau Wai Cheung; Carlos A Bacino; Paweł Stankiewicz
Journal:  Eur J Hum Genet       Date:  2014-10-15       Impact factor: 4.246

Review 3.  Genetics, molecular biology, and phenotypes of x-linked epilepsy.

Authors:  Hao Deng; Wen Zheng; Zhi Song
Journal:  Mol Neurobiol       Date:  2013-11-22       Impact factor: 5.590

4.  Synaptic synthesis, dephosphorylation, and degradation: a novel paradigm for an activity-dependent neuronal control of CDKL5.

Authors:  Paolo La Montanara; Laura Rusconi; Albina Locarno; Lia Forti; Isabella Barbiero; Marco Tramarin; Chetan Chandola; Charlotte Kilstrup-Nielsen; Nicoletta Landsberger
Journal:  J Biol Chem       Date:  2015-01-02       Impact factor: 5.157

5.  CDKL5-Related Disorders: From Clinical Description to Molecular Genetics.

Authors:  N Bahi-Buisson; T Bienvenu
Journal:  Mol Syndromol       Date:  2011-09-13

6.  Recommendations by the ClinGen Rett/Angelman-like expert panel for gene-specific variant interpretation methods.

Authors:  Dianalee McKnight; Lora Bean; Izabela Karbassi; Katelynn Beattie; Thierry Bienvenu; Hope Bonin; Ping Fang; John Chrisodoulou; Michael Friez; Maria Helgeson; Rahul Krishnaraj; Linyan Meng; Lindsey Mighion; Jeffrey Neul; Alan Percy; Simon Ramsden; Huda Zoghbi; Soma Das
Journal:  Hum Mutat       Date:  2021-12-02       Impact factor: 4.700

7.  Mutations in the C-terminus of CDKL5: proceed with caution.

Authors:  Bertrand Diebold; Chloé Delépine; Svetlana Gataullina; Andrée Delahaye; Juliette Nectoux; Thierry Bienvenu
Journal:  Eur J Hum Genet       Date:  2013-06-12       Impact factor: 4.246

Review 8.  What we know and would like to know about CDKL5 and its involvement in epileptic encephalopathy.

Authors:  Charlotte Kilstrup-Nielsen; Laura Rusconi; Paolo La Montanara; Dalila Ciceri; Anna Bergo; Francesco Bedogni; Nicoletta Landsberger
Journal:  Neural Plast       Date:  2012-06-17       Impact factor: 3.599

9.  Deletion of protein tyrosine phosphatase, non-receptor type 4 (PTPN4) in twins with a Rett syndrome-like phenotype.

Authors:  Sarah L Williamson; Carolyn J Ellaway; Greg B Peters; Gregory J Pelka; Patrick P L Tam; John Christodoulou
Journal:  Eur J Hum Genet       Date:  2014-11-26       Impact factor: 4.246

10.  CDKL5 regulates flagellar length and localizes to the base of the flagella in Chlamydomonas.

Authors:  Lai-Wa Tam; Paul T Ranum; Paul A Lefebvre
Journal:  Mol Biol Cell       Date:  2013-01-02       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.